Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

Although HER2-targeted therapies have become a mainstay in cancer treatment, some tumors evade them by stripping away the portion of the HER2 receptor that most therapies are built to recognize and ...

Researchers at the Ragon Institute have made a significant discovery about how antibodies can directly enhance the body's ...

A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have ...

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big ...

Johnson & Johnson's much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and the drugmaker has now filed for FDA approval of a second candidate.

Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate ...

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) ...